Pharmaceutical Product Development, LLC (PPD)
and ERT
today announced a strategic partnership to facilitate delivery of ERT’s
comprehensive solutions for patient safety and efficacy endpoint data
collection to help biopharmaceutical clients conduct clinical trials in
a more efficient and cost-effective manner.
PPD and ERT will work closely throughout all areas of the clinical
development process to offer clients efficiencies through alignment
of crucial aspects of service delivery, including budget and proposal
development, study
startup, data
management and invoicing.
“ERT’s advanced technology in centralized cardiac safety, respiratory
services and clinical outcome assessments (COA) complements PPD’s robust
client offerings across our Phase I-IV clinical trials business,” said
Paul Colvin, PPD’s executive vice president of clinical development.
“ERT has an exemplary reputation in providing these services, and this
partnership enhances PPD’s development capabilities across all
therapeutic areas, with distinct advantages for respiratory,
cardiovascular and late phase trials.”
The agreement with ERT expands PPD's ability to provide high-quality,
integrated resources spanning the drug
development continuum – from early phase studies through regulatory
approval. PPD's operational expertise and global footprint offer ERT an
opportunity to expand its reach and provide increased efficiencies in
clinical trial deployment as it grows its strong customer base.
“ERT is proud to partner with PPD, a global leader in clinical
development,” said Jim Corrigan, president and chief executive officer
of ERT. “PPD and ERT share a common vision of transforming drug
development through the power of technology and clinical services. The
combined expertise, experience and commitment to client success of ERT
and PPD will help drive industry innovation and the development of new
therapies.”
About PPD
PPD is a leading global contract
research organization providing drug
discovery, development, lifecycle management and laboratory
services. Our clients and partners include pharmaceutical,
biotechnology,
medical
device, academic and government
organizations. With offices in 46 countries and more than 13,000
professionals worldwide, PPD applies innovative technologies,
therapeutic expertise and a commitment to quality to help clients and
partners accelerate the delivery of safe and effective therapeutics and
maximize the returns on their R&D investments. For more information,
visit www.ppdi.com.
About ERT
ERT (www.ert.com)
is a leading provider of high-quality patient safety and efficacy data
collection solutions for use in clinical drug development and healthcare
settings. ERT delivers the most widely deployed solutions in centralized
cardiac safety, respiratory services, suicide risk assessment and
clinical outcome assessments (COA) – which includes patient, clinician
and observer reported outcomes. By efficiently integrating these
solutions through a system built upon a scientific and regulatory
foundation, ERT is able to increase the accuracy and reliability of
patient data that it collects, analyzes and delivers. ERT is a global
organization with headquarters in Philadelphia, Pa., and offices
throughout the U.S., U.K., Japan and Germany.
PPD Forward-Looking Statement
Except for historical information, all of the statements,
expectations and assumptions, including statements, expectations and
assumptions about the PPD and ERT partnership, contained in this news
release are forward-looking statements that involve a number of risks
and uncertainties. Although PPD attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances
might differ from the assumptions on which such statements are based and
could cause actual results to differ materially from the forward-looking
statements. Other important factors that could cause future results to
differ materially include the following: the ability to attract,
integrate, retain and train key personnel; competition in the
outsourcing industry; rapid technological advances that make our
services or capabilities less competitive; compliance with drug
development regulations; changes in the regulation of the drug
development process; PPD’s ability to win new business; overall global
economic conditions; economic conditions, research and development
spending, and outsourcing trends in the pharmaceutical, biotechnology
and government-sponsored research sectors; consolidation in the
pharmaceutical and biotechnology industries; loss, delay or modification
of large contracts; higher-than-expected cancellation rates; the rate of
conversion of backlog into revenue; risks associated with and dependence
on strategic relationships; actual operating performance; risks
associated with acquisitions and investments; and the ability to control
SG&A spending. PPD assumes no obligation and expressly disclaims any
duty to update these forward-looking statements in the future, except as
required by applicable law. These forward-looking statements should not
be relied upon as representing PPD’s estimates or views as of any date
subsequent to the date hereof.
Copyright Business Wire 2014